EcoDrugPlus

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSIPUG00000002663
Gene Symbol: GRIK1
4 Cross references
248 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSIPUG00000017281
Gene Symbol: GRIK2
3 Cross references
251 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSIPUG00000014117
Gene Symbol: GRIK2
4 Cross references
192 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSIPUG00000015183
Gene Symbol: GRIK3
3 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSIPUG00000011572
Gene Symbol: GRIK4
2 Cross references
249 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSIPUG00000023655
Gene Symbol: GRM4
3 Cross references
206 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSIPUG00000019519
Gene Symbol: GRM4
4 Cross references
206 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2d

Ensembl ID : ENSIPUG00000007869
Gene Symbol: LOC108276343
2 Cross references
212 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 1a

Ensembl ID : ENSIPUG00000018516
Gene Symbol: GRIA1A
3 Cross references
251 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 1b

Ensembl ID : ENSIPUG00000020437
Gene Symbol: GRIA1B
4 Cross references
249 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 2a

Ensembl ID : ENSIPUG00000001923
Gene Symbol: GRIA2A
4 Cross references
242 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 2b

Ensembl ID : ENSIPUG00000003420
Gene Symbol: GRIA2B
3 Cross references
225 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).